Cargando…

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction

Heart failure (HF) with preserved ejection (HFpEF) constitutes a large and growing proportion of patients with HF around the world, and is now responsible for more than half of all HF cases in ageing societies. While classically described as a condition of elderly, hypertensive women, recent studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teramoto, Kanako, Teng, Tiew-Hwa Katherine, Chandramouli, Chanchal, Tromp, Jasper, Sakata, Yasuhiko, Lam, Carolyn SP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2022
Materias:	Patients with HFpEF
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379774/ https://www.ncbi.nlm.nih.gov/pubmed/35991117 http://dx.doi.org/10.15420/cfr.2022.06

Ejemplares similares

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Fukuta, Hidekatsu
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
por: Bilak, Joanna M, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure
por: Packer, Milton
Publicado: (2021)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
por: Oduah, Mary-Tiffany, et al.
Publicado: (2023)

Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
por: Vijay, Aishwarya, et al.
Publicado: (2023)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction
por: Yap, Jonathan, et al.
Publicado: (2019)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
por: Tay, Wan Ting, et al.
Publicado: (2021)

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
por: Voors, Adriaan A., et al.
Publicado: (2020)

Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure: Insights From ASIAN-HF
por: Aung, Than, et al.
Publicado: (2021)

Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta‐analysis
por: Danielson, Cecilia, et al.
Publicado: (2022)

Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN‐HF Registry
por: MacDonald, Michael R., et al.
Publicado: (2019)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis
por: Jin, Xuanyi, et al.
Publicado: (2022)

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
por: Cooper, Trond J., et al.
Publicado: (2022)

Patient‐reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence
por: Huang, Weiting, et al.
Publicado: (2020)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

Patient-Reported Status and Heart Failure Outcomes in Asia by Sex, Ethnicity, and Socioeconomic Status
por: Lawson, Claire A., et al.
Publicado: (2023)

Association Between Diabetes, Chronic Kidney Disease, and Outcomes in People With Heart Failure From Asia
por: Lawson, Claire A., et al.
Publicado: (2023)

Breakthrough in heart failure with preserved ejection fraction: are we there yet?
por: Lim, Shir Lynn, et al.
Publicado: (2016)

Prevalence, clinical correlates, and outcomes of anaemia in multi‐ethnic Asian patients with heart failure with reduced ejection fraction
por: Goh, Vera J., et al.
Publicado: (2018)

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
por: Tromp, Jasper, et al.
Publicado: (2017)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Incidence, Clinical Correlates, and Prognostic Impact of Dementia in Heart Failure: A Population-Based Cohort Study
por: Ren, Qing-wen, et al.
Publicado: (2023)

Circulating neuregulin1‐β in heart failure with preserved and reduced left ventricular ejection fraction
por: Hage, Camilla, et al.
Publicado: (2020)

Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction
por: Sharma, Abhinav, et al.
Publicado: (2022)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta‐analysis of COMPANION and CARE‐HF
por: Cleland, John G.F., et al.
Publicado: (2022)

Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction
por: Bai, Bo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oem92vnb0sa501tqfk1tppab9q